Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Chatelut

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineF Lokiec, P Canal, C Gay, et al.
Cancer Research|October 15, 1993
Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomasP Canal, M Attal, E Chatelut, et al.
British Journal of Cancer|July 17, 1999
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissuesS Guichard, C Terret, I Hennebelle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1991
Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studiesE Chatelut, M de Forni, P Canal, et al.
Bulletin Du Cancer|August 1, 1997
[Inefficacy of exchange-transfusion in case of a methotrexate poisoning]S Bénézet, E Chatelut, H Bagheri, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 1998
Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4B Monsarrat, E Chatelut, I Royer, et al.
Journal of the American Society of Nephrology : JASN|December 16, 1998
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implicationsL Rostaing, E Chatelut, J L Payen, et al.
British Journal of Cancer|January 22, 2004
Factors affecting pharmacokinetic variability of oral topotecan: a population analysisF Léger, W J Loos, J Fourcade, et al.
Nephron|January 1, 1994
Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiencyE Chatelut, L Rostaing, V Gualano, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Population pharmacokinetics of total and unbound etoposideL Nguyen, E Chatelut, C Chevreau, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineF Lokiec, P Canal, C Gay, et al.
Cancer Research|October 15, 1993
Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomasP Canal, M Attal, E Chatelut, et al.
British Journal of Cancer|July 17, 1999
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissuesS Guichard, C Terret, I Hennebelle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1991
Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studiesE Chatelut, M de Forni, P Canal, et al.
Bulletin Du Cancer|August 1, 1997
[Inefficacy of exchange-transfusion in case of a methotrexate poisoning]S Bénézet, E Chatelut, H Bagheri, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 4, 1998
Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4B Monsarrat, E Chatelut, I Royer, et al.
Journal of the American Society of Nephrology : JASN|December 16, 1998
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implicationsL Rostaing, E Chatelut, J L Payen, et al.
British Journal of Cancer|January 22, 2004
Factors affecting pharmacokinetic variability of oral topotecan: a population analysisF Léger, W J Loos, J Fourcade, et al.
Nephron|January 1, 1994
Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiencyE Chatelut, L Rostaing, V Gualano, et al.
Cancer Chemotherapy and Pharmacology|January 27, 1998
Population pharmacokinetics of total and unbound etoposideL Nguyen, E Chatelut, C Chevreau, et al.
Pageof 8